In previous studies, we have described the role of ADAM8 as a protease involved in TMZ-induced chemoresistance and enhanced invasion of GB cells, already hinting at a possible therapeutic target [75], but in light of the results gathered in the present work, a combination of ADAM8 targeting and anti-PD-1 immunotherapy may be even more effective and is one possible mechanism by which the tumor microenvironment in GB could be made more susceptible to immunotherapy. This evidence concerns the gene ADAM8 and neoplasm.